prescription

United States President Donald Trump has unveiled a second deal with a major pharmaceutical company to offer lower-cost prescription drugs direct to American consumers.

This time, the agreement concerned AstraZeneca, a multinational based in the United Kingdom.

Trump hosted the company’s chief executive, Pascal Soriot, in the Oval Office on Friday to publicly cement the deal, which he described as “another historic achievement in our quest to lower drug prices for all Americans”.

“Americans can expect discounts, and as I said, it could be, in many cases, way over a hundred percent,” Trump said.

As in previous press appearances, he pledged US consumers would see impossible discounts on popular medications.

Inhalers to treat asthma, for example, would be discounted by 654 percent, Trump said, calling the device a “drug that’s hot, very hot”. He also reiterated past claims that some medications could see “a thousand percent reduction”.

Trump has long pushed to reduce prescription drug costs to what he has billed as “most-favoured nations prices”.

That would bring prices down to the same level as in other developed countries, though Trump, with typical hyperbole, has said the policy would equate to “the  lowest price anywhere in the world”.

AstraZeneca is the second major pharmaceutical company after Pfizer to strike such a bargain. Last month, Pfizer announced a “voluntary agreement” to price its products “at parity with other key developed markets”.

Like AstraZeneca, it also agreed to participate in an online, direct-to-consumer marketplace the Trump administration plans to launch, called TrumpRx.

But in a news release on its website, Pfizer made clear that the agreement would help it dodge the high tariffs that Trump threatened against overseas pharmaceutical manufacturers.

“We now have the certainty and stability we need on two critical fronts, tariffs and pricing, that have suppressed the industry’s valuations to historic lows,” Pfizer CEO Albert Bourla said.

At Friday’s Oval Office ceremony, officials like Health and Human Services Secretary Robert F Kennedy Jr openly celebrated the power Trump had wielded through his tariff threats.

“ The president saw something that we didn’t see, which is we had leverage, and that came through Howard [Lutnick] and the tariffs,” Kennedy said, giving a nod to Trump’s commerce secretary. “We had extraordinary leverage to craft these deals.”

The deals with both AstraZeneca and Pfizer came after Trump threatened in September to impose a 100-percent tariff on pharmaceutical companies unless they started to build manufacturing plants in the US.

“There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started,” Trump wrote on his platform, Truth Social.

Those tariffs were slated to come into effect on October 1. But Pfizer unveiled its deal with the Trump administration on September 30, and the tariffs were subsequently postponed.

In Friday’s Oval Office appearance, Soriot acknowledged that, like Pfizer, he had negotiated a delay for any tariffs against AstraZeneca. In exchange, he pledged to increase US investments to $50bn by 2030.

“I appreciate very much Secretary Lutnick granting us a three-year tariff exemption to localise the remainder of our products,” Soriot said. “Most of our products are locally manufactured, but we need to transfer the remaining part to this country.”

Just one day earlier, AstraZeneca had revealed it would construct a “multi-billion-dollar drug substance manufacturing centre” in Virginia, with a focus on chronic diseases, a top priority for the Trump administration.

Trump himself touted his tariff threat as the impetus for the recent string of drug deals. When asked by a reporter if he could have brought the pharmaceutical companies to the negotiating table any other way, Trump was blunt.

“ I would never have been able to bring him,” he replied, with a gesture to Soriot. “ Now, I’m not sure that Pascal would like to say, but behind the scenes, he did say tariffs were a big reason he came here.”

Since returning for a second term as president, the Republican leader has relied heavily on tariffs – and the threats of tariffs – as a cudgel to bring foreign governments and businesses in line with his administration’s priorities.

He has called the term “tariff” the “most beautiful word” in the dictionary and repeatedly labelled the dates he unveiled such import taxes as “Liberation Day”.

But earlier this year, it was unclear if his sabre-rattling would pay dividends. In May, for instance, Trump issued an executive action calling on his government to take “all necessary and appropriate action” to penalise countries whose policies he understood as driving up US drug costs.

He also called on Secretary Kennedy to lay the groundwork for “direct-to-consumer” purchasing programmes where pharmaceutical companies could sell their products at a discount.

Trump, however, lacked a legal mechanism to force participation in such a programme.

In July, he upped the pressure, sending letters to major pharmaceutical manufacturers. The letters warned the drug-makers to bring down prices, or else the government would “deploy every tool in our arsenal” to end the “abusive drug pricing practices”.

He also openly mused that month about hiking tariffs on imported medications.

“We’ll be announcing something very soon on pharmaceuticals,” Trump told a July cabinet meeting. “We’re going to give people about a year, a year and a half, to come in, and after that, they’re going to be tariffed if they have to bring the pharmaceuticals into the country, the drugs.”

“They’re going to be tariffed at a very, very high rate, like 200 percent,” he added.

The “most-favoured nation” pricing scheme is an idea that Trump tried but failed to initiate during his first term as president, from 2017 to 2021.

How that project might shape up in his second term remains to be seen. The TrumpRx website – which the president insists he did not name himself – has yet to offer any services.

Those are expected in 2026.

Seniors in some parts of the country say they are being denied COVID-19 vaccinations amid an ongoing spike in cases, leading to rising frustration over new Trump administration policies that are making it harder to get the shots.

Matthew D’Amico, 67, of New York City, said a Walgreens declined to administer COVID-19 vaccines to him and his 75-year-old wife on Friday because they didn’t have a prescription. They’re trying to get vaccinated ahead of a trip.

“I can’t believe we can’t get” the vaccine, D’Amico said in an interview. “I’ve been inoculated a number of times and never had to get a prescription. And it’s just very frustrating that this is where we are.”

He’s not alone in his exasperation. Under the leadership of the vaccine skeptic Health and Human Services Secretary Robert F. Kennedy Jr., federal agencies have effectively made it more difficult to get vaccinated against COVID-19 this year. The Food and Drug Administration has only “approved” COVID-19 vaccines for those age 65 and up, as well as younger people with underlying health conditions.

That means across the country, people younger than 65 interested in getting the COVID-19 vaccine must now either consult with a healthcare provider or “attest” to a pharmacy that they have an underlying health condition. It’s a potential hurdle that can make getting the vaccine more difficult and, some health experts worry, prompt even more Americans to eschew getting vaccinated.

As D’Amico can attest, though, being part of a group for whom the COVID vaccine is “approved” doesn’t necessarily guarantee easy access.

“For me to go to my primary [healthcare provider] now and get a prescription, it’s just kind of ridiculous,” D’Amico said.

At least some people younger than 65 are encountering pharmacy staff asking probing questions about their medical conditions.

That happened Friday at a CVS in Orange County, according to 34-year-old Alex Benson, who takes medication that can suppress his immune system.

Besides just protecting himself, he wanted to get vaccinated as he has family members who are at high risk should they get COVID — his mother is immunocompromised, and his mother-in-law had open-heart surgery on Thursday night.

Benson said an employee asked why he thought he was eligible for the vaccine.

“They asked me for either a prescription or they wanted to know … why I felt I needed the vaccination,” Benson said. At one point, a staffer offered to call his doctor to get an authorization for the vaccine.

Benson said he was alarmed by the questions, and started to “feel kind of some desperation to plead my case to the pharmacist.” Another CVS staffer later came over and said further answers weren’t necessary and simply attesting he was eligible was good enough. He eventually got the vaccine.

Still, he felt the experience was dismaying.

“I think easy access should be the policy,” Benson said. “I tend not to get too political, but it seems just rather juxtaposed to me that an anti-regulation administration is using regulation in this way. They’re supposed to be removing barriers to healthcare.”

The vaccine chaos comes as COVID-19 is either increasing or starting to hit its late summer peak. According to data released Friday, there are now 14 states with “very high” levels of coronavirus detected in their wastewater — California, Texas, Florida, North Carolina, Indiana, South Carolina, Alabama, Louisiana, Connecticut, Utah, Nevada, Idaho, Hawaii and Alaska, as well as the District of Columbia.

Dr. Elizabeth Hudson, the regional physician chief of infectious diseases for Kaiser Permanente Southern California, said data continue to show an increase in coronavirus cases.

“Over this past week, we’ve seen an increase in the number of outpatient COVID cases, and even a smattering of inpatient cases,” Hudson said. “It appears that we may be nearing the top of the wave, but it may be another two weeks or so until we truly know if we’re there.”

The rate at which coronavirus lab tests are confirming infection also continues to rise statewide and in the Los Angeles area. For the week ending Aug. 30, California’s COVID test positivity rate was 12.83%, up from 7.05% for the week ending Aug. 2. In L.A. County, the positive test rate was 14.83%, up from 9.33%.

Other data, however, suggest some areas may have reached their summer COVID peak.

In Orange County, the COVID positive test rate was 13.1%. That’s below the prior week’s rate of 18%, but still higher than the rate for the week that ended Aug. 2, which was 10.8%.

In San Francisco, the test positivity rate has been hovering around 9% for the last week of reliable data available. It’s up from 7% a month earlier.

In addition, wastewater data in L.A. County show coronavirus levels declined slightly from the prior week.

“It’s too early to know if this decrease in wastewater viral concentrations is the first sign that COVID-19 activity is peaking or is regular variation typical of this data source,” the L.A. County Department of Public Health said.

COVID hospital admissions in California are increasing — with the latest rate of 3.93 admissions per 100,000 residents, up from 2.38.

But they remain relatively low statewide and in L.A. County. The number of L.A. County residents seeking care for COVID-related illness, or who have been hospitalized, “is quite a bit lower than during summer surges in 2023 and 2024,” the public health department said.

A relatively mild summer wave, however, could mean that the annual fall-and-winter COVID wave might be stronger. In July, the state Department of Public Health said that scientists anticipate California would see either a stronger summer COVID wave or a more significant winter wave.

The current confusion over federal COVID vaccine policy has been exacerbated by the chaos at the U.S. Centers for Disease Control and Prevention, where Kennedy earlier this year fired everyone on the influential Advisory Committee on Immunization Practices, and orchestrated the firing of CDC Director Susan Monarez just 29 days after she was confirmed to the post by the Senate.

Some of Kennedy’s handpicked replacements on the ACIP have criticized vaccines and spread misinformation, according to the Associated Press. And the new interim CDC director — Jim O’Neill, a Kennedy deputy — is a critic of health regulations and has no training in medicine or healthcare, the AP reported.

The CDC hasn’t issued its own recommendations on who should get vaccinated, and that inaction has resulted in residents of a number of states needing to get prescriptions from a healthcare provider for at least the next couple of weeks. In some cases, that’s true even for seniors, as D’Amico found out.

As of Friday, CVS said people need a prescription to get a COVID-19 vaccine, sometimes depending on their age, in Arizona, Florida, Georgia, Louisiana, Maine, North Carolina, New Mexico, New York, Pennsylvania, Utah, Virginia and West Virginia, as well as the District of Columbia.

CVS couldn’t even offer the COVID-19 at its pharmacies in Nevada as of Friday; they were only available at the company’s MinuteClinic sites, according to spokesperson Amy Thibault.

CVS said it expects to offer COVID-19 vaccines without prescriptions at its pharmacies in New Mexico, Nevada, New York and Pennsylvania “soon,” due to recent regulatory changes in each state.

“Right now, all patients in all states need to attest to being eligible for the vaccine in order to schedule an appointment online,” Thibault said. If an adult says they have no underlying health conditions, but do have a prescription from a healthcare provider for “off-label” use of the vaccine, they can get the shot, Thibault confirmed.

On Thursday, Hawaii joined California, Washington and Oregon in launching the West Coast Health Alliance: an interstate compact meant to provide science-based immunization guidance as an alternative to the CDC.

“Together, these states will provide evidence-based immunization guidance rooted in safety, efficacy, and transparency — ensuring residents receive credible information free from political interference,” according to a statement from Gov. Gavin Newsom’s office.

The statement suggested that the Trump administration was essentially “dismantling” the CDC.

“The absence of consistent, science-based federal leadership poses a direct threat to our nation’s health security,” the statement said. “To protect the health of our communities, the West Coast Health Alliance will continue to ensure that our public health strategies are based on best available science.”

It was not immediately clear, however, whether the formation of the West Coast Health Alliance would make it easier for people to get COVID-19 vaccines at the nation’s largest pharmacy retailers, where many people get their shots.

Mainstream medical groups, such as the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists, are also offering their own recommendations to advise individuals and families on what vaccines they should get.

Walmart will soon expand its streaming offerings to its subscription members, with the retail giant announcing a new partnership with NBCUniversal’s Peacock on Monday.

Starting Sept. 15, Walmart+ subscribers can choose to receive ad-supported versions of Peacock Premium or Paramount+ as part of their membership. Every 90 days, Walmart+ members can switch between the two services.

“The additional option of Peacock Premium adds even more value and more choice to our membership, without raising the price,” said Deepak Maini, senior vice president of Walmart+, in a statement. “This is just one of the many ways we’re evolving Walmart+ to meet the needs and wants of today’s consumer.”

The move could appeal to consumers who feel overwhelmed by the different streaming choices and give them a chance to sample what each platform offers without dealing with additional cost.

Walmart+, which charges $98 for an annual plan, includes free shipping, free same-day delivery on groceries and prescriptions, gas discounts and other benefits. Adding more streaming content could help Bentonville, Ark.-based Walmart compete with Amazon Prime, though Walmart does not invest in original content, unlike the Seattle e-commerce behemoth.

Walmart declined to say how many people subscribe to Walmart+.

In 2020, Walmart launched Walmart+, which competes with Amazon’s $139 annual Prime membership. Prime offers perks such as free shipping and streaming series such as “The Summer I Turned Pretty” and “Reacher,” action movie “The Pickup” and NFL football games.

Last week, Amazon announced that Peacock Premium Plus, the streaming service’s ad-free version, would be available on Prime Video for an additional fee, along with 100 other subscription options in the U.S. Amazon also said it had a multiyear deal for the Peacock app to be available on its Fire TV in the U.S.

Walmart has had a spotty track record on its own streaming efforts and currently does not have its own streaming service or produce its own originals. In 2010, Walmart purchased video-on-demand service Vudu and in 2018 partnered with MGM to create original programming for the platform. The retailer later sold Vudu to Fandango in 2020.

Before that, Walmart launched a web store to sell movie and TV show downloads but shut it down in less than a year after its partner, Hewlett-Packard Co., discontinued the technology for the site after it underperformed.